Entera Bio (ENTX) Return on Sales (2019 - 2025)
Entera Bio has reported Return on Sales over the past 7 years, most recently at 2.74% for Q4 2025.
- For the quarter ending Q4 2025, Return on Sales fell 245.0% year-over-year to 2.74%, compared with a TTM value of 2.74% through Dec 2025, down 221.0%, and an annual FY2025 reading of 2.72%, down 220.0% over the prior year.
- Return on Sales came in at 2.74% for Q4 2025, down from 0.87% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.15% in Q1 2021 to a low of 7.09% in Q3 2023.
- Median Return on Sales over the past 5 years was 0.68% (2024), compared with a mean of 1.56%.
- The sharpest move saw Return on Sales plummeted -410bps in 2023, then skyrocketed 637bps in 2024.
- Over 5 years, Return on Sales stood at 0.25% in 2021, then crashed by -772bps to 2.17% in 2022, then crashed by -227bps to 7.09% in 2023, then surged by 96bps to 0.29% in 2024, then tumbled by -854bps to 2.74% in 2025.
- Per Business Quant, the three most recent readings for ENTX's Return on Sales are 2.74% (Q4 2025), 0.87% (Q3 2025), and 0.64% (Q2 2025).